In conclusion, the development of drugs aimed to both trigger PTPRJ activity and inhibit CD98hc signaling in combination, could represent an intriguing opportunity for the treatment of cancer patients with poor prognosis, based on the simultaneous targeting of several hallmarks important in the biology of a cancer cell [54], including proliferation, apoptosis, angiogenesis, and energetic metabolism. The gene discussed is SLC3A2; the disease is cancer.